Cargando…

Evaluation of Consistency of Treatment Response Across Regions—the LEADER Trial in Relation to the ICH E17 Guideline

The US Food and Drug Administration in 2008 required new type 2 diabetes (T2D) medications to be subject to cardiovascular outcomes safety requirements. Accordingly, the global LEADER trial investigated cardiovascular outcomes of T2D treatment with liraglutide, a glucagon-like peptide-1 receptor ago...

Descripción completa

Detalles Bibliográficos
Autores principales: Nielsen, Henrik K., DeChiaro, Stephanie, Goldman, Bryan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8201994/
https://www.ncbi.nlm.nih.gov/pubmed/34136501
http://dx.doi.org/10.3389/fmed.2021.662775